Leader Biomedical Group has established its Inovações Biológicas Comercial LTDA, expanding its commercial operations to South America. This new company will start registering Leader’s portfolio of biomaterials from its base in São Paulo.
Leader Biomedical Group supplies a number of bone graft substitutes; including animal- and human-derived grafts processed with its eCOO technology, such as the eTiss demineralised bone matrix. According to Leader, eCOO uses supercritical CO2 to clean and sterilise allografts and xenografts, and has been shown to be more effective than conventional methods at preserving the tissue’s native crosslinking. This factor is associated with shorter patient recovery times, according to a press release.
“We expect the eCOO technology platform, and our line of biomaterials, will fill a gap in the national market and increase access to robust technologies and proven products at an affordable cost of care,” explains Basil Babychan, business director leader Biomedical Group, who adds that the company is very pleased to be partnering with business executive and orthopaedic surgeon, Caio Goncalves de Souza.
“I am truly pleased to join Leader Biomedical Group in this venture,” comments Caio Gonçalves de Souza, managing director of Inovações Biológicas Comercial LTDA. “We expect to start the registration of niche biomaterials and implants, for dental and orthopedic applications before the end of this year.”
The incorporation of Leader Biomedical Brazil follows the establishment of Leader Biomedical India, which is already operational.
